Funding
← Back to your selection

Novo Holdings

Activity from announced rounds

Activity in this selectionEurope

Novo Holdings manages the Novo Nordisk Foundation’s investment assets and invests in healthcare and life sciences across development stages.

Investment focus

The foundation-owned holding and investment company combines a broad long-term asset portfolio with dedicated healthcare and life-sciences investment teams. Its activities include seed, venture, planetary health and principal investments.

Activity recorded by RoundOS

Recorded financing includes AnaCardio’s heart-failure drug development, Adcendo’s antibody-drug conjugates, Terremoto’s small-molecule programs and Crystalys’ gout treatment candidate. These entries show selected therapeutic investments in the database, spanning different disease areas and clinical programs.

Sources
Rounds participated in
5
Confirmed lead rounds
4
1 roles undisclosed
New companies
4
First participation on record · 1 follow-on
Funding in participating rounds
$536.6M
5 disclosed · full round size, not this investor’s share

By stage

Series C+2
Seed1
Series A1
Series B1

By primary sector

Biotech5

By country

Denmark3
Sweden1
United Kingdom1

Rounds

5 in this selection
OMass Therapeutics

OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.

$310MSeries C
Lead
AnaCardio

AnaCardio develops oral medicines intended to improve heart muscle contraction in people with heart failure.

€62.5MSeries B
Lead
Adcendo

Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.

$75MSeries C
Role not disclosed